Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 8/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.47 |
| ▸ | GABRP | O00591 | 7/20 | 0.47 |
| ▸ | GABRD | O14764 | 7/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 7/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.47 |
| ▸ | GABRE | P78334 | 7/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 7/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 7/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 7/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72539 | 0.85 | TRPC6 (0.44) | MAPTALDH1A1MAPK1GABRA1GABRG2 | |
| SCHEMBL1424950 | 0.81 | GABRA1 (0.50) | MAPTALDH1A1MAPK1GABRA1GABRG2 | |
| SCHEMBL71748 | 0.81 | KMO (0.45) | KDM4ETRPC6 | |
| SCHEMBL21045683 | 0.80 | TRPC6 (0.49) | MAPTALDH1A1MAPK1GABRA1GABRG2 | |
| SCHEMBL1425478 | 0.80 | GABRA1 (0.46) | MAPTALDH1A1MAPK1GABRA1GABRG2 | |
| SCHEMBL1424815 | 0.78 | GABRP (0.48) | MAPTALDH1A1MAPK1GABRA1GABRG2 | |
| SCHEMBL22978588 | 0.78 | GABRA1 (0.48) | MAPTALDH1A1MAPK1GABRA1GABRG2 | |
| SCHEMBL17440116 | 0.78 | GABRA1 (0.47) | MAPTALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL17440157 | 0.77 | DPP4 (0.46) | MAPTALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL22890358 | 0.75 | HPGD (0.47) | MAPTALDH1A1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-7652144-B2 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-7045660-B2 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | FENTON GARRY (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6472412-B1 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0711282-B1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | AVENTIS PHARMA LTD (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE4C | MAPT 4331/4885ALDH1A1 1572/4885MAPK1 759/4885 |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | MAPT 4353/4885ALDH1A1 1357/4885MAPK1 791/4885 |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | MAPT 4460/4885ALDH1A1 1364/4885MAPK1 818/4885 |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | MAPT 4460/4885ALDH1A1 1364/4885MAPK1 818/4885 |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | MAPT 4353/4885ALDH1A1 1357/4885MAPK1 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.